Jazz Pharmaceuticals (NASDAQ:JAZZ) Stock Price Expected to Rise, Wells Fargo & Company Analyst Says

Jazz Pharmaceuticals (NASDAQ:JAZZ) had its target price hoisted by equities researchers at Wells Fargo & Company from $250.00 to $265.00 in a report issued on Wednesday,Benzinga reports. The firm presently has an “overweight” rating on the specialty pharmaceutical company’s stock. Wells Fargo & Company‘s price target suggests a potential upside of 17.32% from the stock’s previous close.

A number of other analysts have also commented on JAZZ. TD Cowen reaffirmed a “buy” rating on shares of Jazz Pharmaceuticals in a research report on Thursday, January 29th. Needham & Company LLC boosted their price objective on Jazz Pharmaceuticals from $210.00 to $235.00 and gave the stock a “buy” rating in a report on Monday, January 12th. Piper Sandler boosted their target price on Jazz Pharmaceuticals from $219.00 to $232.00 and gave the stock an “overweight” rating in a research note on Thursday, March 19th. Royal Bank Of Canada boosted their target price on Jazz Pharmaceuticals from $191.00 to $195.00 and gave the stock an “outperform” rating in a research note on Wednesday, February 25th. Finally, Morgan Stanley upped their price objective on Jazz Pharmaceuticals from $225.00 to $226.00 and gave the company an “overweight” rating in a research note on Wednesday, February 25th. One investment analyst has rated the stock with a Strong Buy rating, fourteen have assigned a Buy rating, two have assigned a Hold rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat.com, Jazz Pharmaceuticals currently has an average rating of “Moderate Buy” and an average price target of $221.33.

Jazz Pharmaceuticals Price Performance

Shares of NASDAQ JAZZ traded up $13.63 during mid-day trading on Wednesday, hitting $225.89. 277,431 shares of the stock traded hands, compared to its average volume of 992,150. The company has a debt-to-equity ratio of 1.00, a current ratio of 1.86 and a quick ratio of 1.67. Jazz Pharmaceuticals has a twelve month low of $97.50 and a twelve month high of $230.40. The company has a market cap of $14.17 billion, a PE ratio of -37.86, a price-to-earnings-growth ratio of 0.36 and a beta of 0.27. The firm has a 50 day simple moving average of $190.45 and a two-hundred day simple moving average of $171.65.

Jazz Pharmaceuticals (NASDAQ:JAZZ) last announced its earnings results on Tuesday, March 31st. The specialty pharmaceutical company reported $6.34 earnings per share (EPS) for the quarter. The business had revenue of $1.07 billion during the quarter. Jazz Pharmaceuticals had a positive return on equity of 6.87% and a negative net margin of 8.35%. As a group, equities research analysts forecast that Jazz Pharmaceuticals will post 20.51 EPS for the current fiscal year.

Insider Buying and Selling

In related news, CAO Patricia Carr sold 1,287 shares of the stock in a transaction on Monday, March 9th. The stock was sold at an average price of $182.94, for a total value of $235,443.78. Following the sale, the chief accounting officer owned 6,512 shares in the company, valued at approximately $1,191,305.28. This trade represents a 16.50% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is accessible through the SEC website. Also, SVP Mary Elizabeth Henderson sold 5,343 shares of the stock in a transaction on Thursday, February 26th. The shares were sold at an average price of $194.49, for a total value of $1,039,160.07. Following the completion of the transaction, the senior vice president directly owned 28,728 shares in the company, valued at approximately $5,587,308.72. This represents a 15.68% decrease in their position. The SEC filing for this sale provides additional information. Insiders have sold a total of 74,015 shares of company stock valued at $14,180,486 in the last ninety days. 4.30% of the stock is owned by insiders.

Institutional Inflows and Outflows

A number of institutional investors have recently added to or reduced their stakes in the company. Bessemer Group Inc. increased its stake in Jazz Pharmaceuticals by 0.3% in the first quarter. Bessemer Group Inc. now owns 22,362 shares of the specialty pharmaceutical company’s stock valued at $4,228,000 after acquiring an additional 73 shares during the last quarter. Bank of New York Mellon Corp increased its stake in Jazz Pharmaceuticals by 44.5% in the first quarter. Bank of New York Mellon Corp now owns 1,679,371 shares of the specialty pharmaceutical company’s stock valued at $317,485,000 after acquiring an additional 517,514 shares during the last quarter. Illinois Municipal Retirement Fund increased its stake in Jazz Pharmaceuticals by 26.7% in the first quarter. Illinois Municipal Retirement Fund now owns 61,883 shares of the specialty pharmaceutical company’s stock valued at $11,699,000 after acquiring an additional 13,057 shares during the last quarter. Sanctuary Advisors LLC increased its stake in Jazz Pharmaceuticals by 11.2% in the first quarter. Sanctuary Advisors LLC now owns 2,021 shares of the specialty pharmaceutical company’s stock valued at $382,000 after acquiring an additional 204 shares during the last quarter. Finally, Calamos Advisors LLC bought a new position in Jazz Pharmaceuticals in the first quarter valued at $309,000. Institutional investors own 89.14% of the company’s stock.

Key Jazz Pharmaceuticals News

Here are the key news stories impacting Jazz Pharmaceuticals this week:

• Positive Sentiment: Large EPS beat – Jazz reported $6.34 EPS vs. consensus ~$4.67, a sizeable upside that drove investor enthusiasm for profitability and cash-generation potential. Jazz Pharmaceuticals (JAZZ) Q1 Earnings and Revenues Top Estimates
• Positive Sentiment: Pipeline catalyst — zanidatamab (HER2+ 1L GEA) received Priority Review with a PDUFA date of Aug 25, 2026, creating a clear near-term binary that could materially affect long-term revenues if approved. Jazz Pharmaceuticals Announces First Quarter 2026 Financial Results
• Positive Sentiment: Commercial growth — management highlighted ~19% YoY revenue growth and product-level strength (Xywav and Epidiolex growth; net patient adds), supporting the view that core franchises are expanding. Jazz Pharmaceuticals Announces First Quarter 2026 Financial Results
• Neutral Sentiment: Guidance reaffirmed — the company reiterated 2026 revenue and expense guidance, which reduces uncertainty but leaves investors waiting for full-year detail and cadence. Jazz Pharmaceuticals Announces First Quarter 2026 Financial Results
• Neutral Sentiment: More detail available — the earnings call transcript and slide deck provide management color on growth drivers and cost assumptions for 2026; useful for modeling but not an immediate directional news item. Jazz Pharmaceuticals plc (JAZZ) Q1 2026 Earnings Call Transcript
• Negative Sentiment: Top-line slightly missed Street revenue consensus (reported ~$975M vs. ~$978M estimate), which tempers the beat and suggests some near-term sales variability. Jazz Pharmaceuticals Q1 Results Summary
• Negative Sentiment: GAAP profitability and margins — the company still reported a negative net margin and modest ROE; investors should watch how one-time items, R&D and SG&A trends affect sustained profitability. Jazz Pharmaceuticals Q1 Results Summary

Jazz Pharmaceuticals Company Profile

Jazz Pharmaceuticals plc is a global biopharmaceutical company focused on developing and commercializing therapies in neuroscience and oncology. The company’s research and development efforts target unmet medical needs in sleep disorders, hematologic malignancies, rare neurological conditions and solid tumors. Jazz’s product portfolio includes therapies for narcolepsy, hepatic veno-occlusive disease, acute myeloid leukemia and other serious disorders.

Flagship products from Jazz Pharmaceuticals include Xyrem® (sodium oxybate) and Xywav® (calcium, magnesium, potassium, and sodium oxybates) for the treatment of cataplexy and excessive daytime sleepiness in patients with narcolepsy.